Standardized Definitions of In Utero Human Immunodeficiency Virus and Antiretroviral Drug Exposure Among Children

Abstract In countries with high human immunodeficiency virus (HIV) prevalence, up to 30% of pregnant women are living with HIV, with fetal exposure to both HIV and antiretroviral therapy during pregnancy. In addition, pregnant women without HIV but at high risk of HIV acquisition are increasingly re...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical infectious diseases 2022-08, Vol.75 (2), p.347-355
Hauptverfasser: Slogrove, Amy L, Burmen, Barbara, Davies, Mary Ann, Edmonds, Andrew, Abrams, Elaine J, Chadwick, Ellen G, Goetghebuer, Tessa, Mofenson, Lynne M, Paul, Mary E, Thorne, Claire, Williams, Paige L, Vicari, Marissa, Powis, Kathleen M
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 355
container_issue 2
container_start_page 347
container_title Clinical infectious diseases
container_volume 75
creator Slogrove, Amy L
Burmen, Barbara
Davies, Mary Ann
Edmonds, Andrew
Abrams, Elaine J
Chadwick, Ellen G
Goetghebuer, Tessa
Mofenson, Lynne M
Paul, Mary E
Thorne, Claire
Williams, Paige L
Vicari, Marissa
Powis, Kathleen M
description Abstract In countries with high human immunodeficiency virus (HIV) prevalence, up to 30% of pregnant women are living with HIV, with fetal exposure to both HIV and antiretroviral therapy during pregnancy. In addition, pregnant women without HIV but at high risk of HIV acquisition are increasingly receiving HIV preexposure antiretroviral prophylaxis (PrEP). Investments are being made to establish and follow cohorts of children to evaluate the long-term effects of in utero HIV and antiretroviral exposure. Agreement on a key set of definitions for relevant exposures and outcomes is important both for interpreting individual study results and for comparisons across cohorts. Harmonized definitions of in utero HIV and antiretroviral drug (maternal treatment or PrEP) exposure will also facilitate improved classification of these exposures in future observational studies and clinical trials. The proposed definitions offer a uniform approach to facilitate the consistent description and estimation of effects of HIV and antiretroviral exposures on key child health outcomes. In countries with high human immunodeficiency virus (HIV) prevalence, 20%–30% of pregnant women have HIV and receive antiretrovirals. Proposed definitions offer a uniform approach to describing/estimating the effects of in utero HIV and antiretroviral exposure on child health outcomes.
doi_str_mv 10.1093/cid/ciab974
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9410726</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/cid/ciab974</oup_id><sourcerecordid>2630926273</sourcerecordid><originalsourceid>FETCH-LOGICAL-c412t-73b1d0bfe59d9a74577013acbe5eec09d2f91c91d2c2e2c08989c4c0468abf1a3</originalsourceid><addsrcrecordid>eNp9kc1rGzEQxUVoiNMkp96LTqUQNpX2w5IuBWOnjSGQQ5NchVaatVV2JUdahTp_fRTshuSSwzAD85s3Dx5CXyi5oERUP7Q1uVQrWH2AjmlTsWLaCPopz6ThRc0rPkGfY_xLCKWcNEdoUjWUU8bFMXr4MypnVDD2CQxeQGedHa13EfsOLx2-GyF4fJUG5fByGJLzJjPagtNbfG9Dijjf45kbbYAx-EcbVI8XIa3w5b-NjykAng3erfB8bXsTwJ2iw071Ec72_QTd_bq8nV8V1ze_l_PZdaFrWo4Fq1pqSNtBI4xQrG4YI7RSuoUGQBNhyk5QLagpdQmlJlxwoWtN6ilXbUdVdYJ-7nQ3qR3AaHBjtiY3wQ4qbKVXVr7fOLuWK_8oRU0JK6dZ4PteIPiHBHGUg40a-l458CnKjBBRTktWZfR8h-rgYwzQvb6hRL6EJHNIch9Spr--dfbK_k8lA992gE-bD5WeAX-5ntM</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2630926273</pqid></control><display><type>article</type><title>Standardized Definitions of In Utero Human Immunodeficiency Virus and Antiretroviral Drug Exposure Among Children</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Slogrove, Amy L ; Burmen, Barbara ; Davies, Mary Ann ; Edmonds, Andrew ; Abrams, Elaine J ; Chadwick, Ellen G ; Goetghebuer, Tessa ; Mofenson, Lynne M ; Paul, Mary E ; Thorne, Claire ; Williams, Paige L ; Vicari, Marissa ; Powis, Kathleen M</creator><creatorcontrib>Slogrove, Amy L ; Burmen, Barbara ; Davies, Mary Ann ; Edmonds, Andrew ; Abrams, Elaine J ; Chadwick, Ellen G ; Goetghebuer, Tessa ; Mofenson, Lynne M ; Paul, Mary E ; Thorne, Claire ; Williams, Paige L ; Vicari, Marissa ; Powis, Kathleen M</creatorcontrib><description>Abstract In countries with high human immunodeficiency virus (HIV) prevalence, up to 30% of pregnant women are living with HIV, with fetal exposure to both HIV and antiretroviral therapy during pregnancy. In addition, pregnant women without HIV but at high risk of HIV acquisition are increasingly receiving HIV preexposure antiretroviral prophylaxis (PrEP). Investments are being made to establish and follow cohorts of children to evaluate the long-term effects of in utero HIV and antiretroviral exposure. Agreement on a key set of definitions for relevant exposures and outcomes is important both for interpreting individual study results and for comparisons across cohorts. Harmonized definitions of in utero HIV and antiretroviral drug (maternal treatment or PrEP) exposure will also facilitate improved classification of these exposures in future observational studies and clinical trials. The proposed definitions offer a uniform approach to facilitate the consistent description and estimation of effects of HIV and antiretroviral exposures on key child health outcomes. In countries with high human immunodeficiency virus (HIV) prevalence, 20%–30% of pregnant women have HIV and receive antiretrovirals. Proposed definitions offer a uniform approach to describing/estimating the effects of in utero HIV and antiretroviral exposure on child health outcomes.</description><identifier>ISSN: 1058-4838</identifier><identifier>ISSN: 1537-6591</identifier><identifier>EISSN: 1537-6591</identifier><identifier>DOI: 10.1093/cid/ciab974</identifier><identifier>PMID: 35181789</identifier><language>eng</language><publisher>US: Oxford University Press</publisher><subject>Anti-HIV Agents - adverse effects ; Anti-Retroviral Agents - therapeutic use ; Child ; Female ; HIV ; HIV Infections - prevention &amp; control ; Humans ; Infectious Disease Transmission, Vertical - prevention &amp; control ; Pre-Exposure Prophylaxis ; Pregnancy ; Pregnancy Complications, Infectious - drug therapy ; Viewpoints</subject><ispartof>Clinical infectious diseases, 2022-08, Vol.75 (2), p.347-355</ispartof><rights>The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com. 2021</rights><rights>The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c412t-73b1d0bfe59d9a74577013acbe5eec09d2f91c91d2c2e2c08989c4c0468abf1a3</citedby><cites>FETCH-LOGICAL-c412t-73b1d0bfe59d9a74577013acbe5eec09d2f91c91d2c2e2c08989c4c0468abf1a3</cites><orcidid>0000-0002-8046-9268</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,1578,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35181789$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Slogrove, Amy L</creatorcontrib><creatorcontrib>Burmen, Barbara</creatorcontrib><creatorcontrib>Davies, Mary Ann</creatorcontrib><creatorcontrib>Edmonds, Andrew</creatorcontrib><creatorcontrib>Abrams, Elaine J</creatorcontrib><creatorcontrib>Chadwick, Ellen G</creatorcontrib><creatorcontrib>Goetghebuer, Tessa</creatorcontrib><creatorcontrib>Mofenson, Lynne M</creatorcontrib><creatorcontrib>Paul, Mary E</creatorcontrib><creatorcontrib>Thorne, Claire</creatorcontrib><creatorcontrib>Williams, Paige L</creatorcontrib><creatorcontrib>Vicari, Marissa</creatorcontrib><creatorcontrib>Powis, Kathleen M</creatorcontrib><title>Standardized Definitions of In Utero Human Immunodeficiency Virus and Antiretroviral Drug Exposure Among Children</title><title>Clinical infectious diseases</title><addtitle>Clin Infect Dis</addtitle><description>Abstract In countries with high human immunodeficiency virus (HIV) prevalence, up to 30% of pregnant women are living with HIV, with fetal exposure to both HIV and antiretroviral therapy during pregnancy. In addition, pregnant women without HIV but at high risk of HIV acquisition are increasingly receiving HIV preexposure antiretroviral prophylaxis (PrEP). Investments are being made to establish and follow cohorts of children to evaluate the long-term effects of in utero HIV and antiretroviral exposure. Agreement on a key set of definitions for relevant exposures and outcomes is important both for interpreting individual study results and for comparisons across cohorts. Harmonized definitions of in utero HIV and antiretroviral drug (maternal treatment or PrEP) exposure will also facilitate improved classification of these exposures in future observational studies and clinical trials. The proposed definitions offer a uniform approach to facilitate the consistent description and estimation of effects of HIV and antiretroviral exposures on key child health outcomes. In countries with high human immunodeficiency virus (HIV) prevalence, 20%–30% of pregnant women have HIV and receive antiretrovirals. Proposed definitions offer a uniform approach to describing/estimating the effects of in utero HIV and antiretroviral exposure on child health outcomes.</description><subject>Anti-HIV Agents - adverse effects</subject><subject>Anti-Retroviral Agents - therapeutic use</subject><subject>Child</subject><subject>Female</subject><subject>HIV</subject><subject>HIV Infections - prevention &amp; control</subject><subject>Humans</subject><subject>Infectious Disease Transmission, Vertical - prevention &amp; control</subject><subject>Pre-Exposure Prophylaxis</subject><subject>Pregnancy</subject><subject>Pregnancy Complications, Infectious - drug therapy</subject><subject>Viewpoints</subject><issn>1058-4838</issn><issn>1537-6591</issn><issn>1537-6591</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kc1rGzEQxUVoiNMkp96LTqUQNpX2w5IuBWOnjSGQQ5NchVaatVV2JUdahTp_fRTshuSSwzAD85s3Dx5CXyi5oERUP7Q1uVQrWH2AjmlTsWLaCPopz6ThRc0rPkGfY_xLCKWcNEdoUjWUU8bFMXr4MypnVDD2CQxeQGedHa13EfsOLx2-GyF4fJUG5fByGJLzJjPagtNbfG9Dijjf45kbbYAx-EcbVI8XIa3w5b-NjykAng3erfB8bXsTwJ2iw071Ec72_QTd_bq8nV8V1ze_l_PZdaFrWo4Fq1pqSNtBI4xQrG4YI7RSuoUGQBNhyk5QLagpdQmlJlxwoWtN6ilXbUdVdYJ-7nQ3qR3AaHBjtiY3wQ4qbKVXVr7fOLuWK_8oRU0JK6dZ4PteIPiHBHGUg40a-l458CnKjBBRTktWZfR8h-rgYwzQvb6hRL6EJHNIch9Spr--dfbK_k8lA992gE-bD5WeAX-5ntM</recordid><startdate>20220825</startdate><enddate>20220825</enddate><creator>Slogrove, Amy L</creator><creator>Burmen, Barbara</creator><creator>Davies, Mary Ann</creator><creator>Edmonds, Andrew</creator><creator>Abrams, Elaine J</creator><creator>Chadwick, Ellen G</creator><creator>Goetghebuer, Tessa</creator><creator>Mofenson, Lynne M</creator><creator>Paul, Mary E</creator><creator>Thorne, Claire</creator><creator>Williams, Paige L</creator><creator>Vicari, Marissa</creator><creator>Powis, Kathleen M</creator><general>Oxford University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-8046-9268</orcidid></search><sort><creationdate>20220825</creationdate><title>Standardized Definitions of In Utero Human Immunodeficiency Virus and Antiretroviral Drug Exposure Among Children</title><author>Slogrove, Amy L ; Burmen, Barbara ; Davies, Mary Ann ; Edmonds, Andrew ; Abrams, Elaine J ; Chadwick, Ellen G ; Goetghebuer, Tessa ; Mofenson, Lynne M ; Paul, Mary E ; Thorne, Claire ; Williams, Paige L ; Vicari, Marissa ; Powis, Kathleen M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c412t-73b1d0bfe59d9a74577013acbe5eec09d2f91c91d2c2e2c08989c4c0468abf1a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Anti-HIV Agents - adverse effects</topic><topic>Anti-Retroviral Agents - therapeutic use</topic><topic>Child</topic><topic>Female</topic><topic>HIV</topic><topic>HIV Infections - prevention &amp; control</topic><topic>Humans</topic><topic>Infectious Disease Transmission, Vertical - prevention &amp; control</topic><topic>Pre-Exposure Prophylaxis</topic><topic>Pregnancy</topic><topic>Pregnancy Complications, Infectious - drug therapy</topic><topic>Viewpoints</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Slogrove, Amy L</creatorcontrib><creatorcontrib>Burmen, Barbara</creatorcontrib><creatorcontrib>Davies, Mary Ann</creatorcontrib><creatorcontrib>Edmonds, Andrew</creatorcontrib><creatorcontrib>Abrams, Elaine J</creatorcontrib><creatorcontrib>Chadwick, Ellen G</creatorcontrib><creatorcontrib>Goetghebuer, Tessa</creatorcontrib><creatorcontrib>Mofenson, Lynne M</creatorcontrib><creatorcontrib>Paul, Mary E</creatorcontrib><creatorcontrib>Thorne, Claire</creatorcontrib><creatorcontrib>Williams, Paige L</creatorcontrib><creatorcontrib>Vicari, Marissa</creatorcontrib><creatorcontrib>Powis, Kathleen M</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Clinical infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Slogrove, Amy L</au><au>Burmen, Barbara</au><au>Davies, Mary Ann</au><au>Edmonds, Andrew</au><au>Abrams, Elaine J</au><au>Chadwick, Ellen G</au><au>Goetghebuer, Tessa</au><au>Mofenson, Lynne M</au><au>Paul, Mary E</au><au>Thorne, Claire</au><au>Williams, Paige L</au><au>Vicari, Marissa</au><au>Powis, Kathleen M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Standardized Definitions of In Utero Human Immunodeficiency Virus and Antiretroviral Drug Exposure Among Children</atitle><jtitle>Clinical infectious diseases</jtitle><addtitle>Clin Infect Dis</addtitle><date>2022-08-25</date><risdate>2022</risdate><volume>75</volume><issue>2</issue><spage>347</spage><epage>355</epage><pages>347-355</pages><issn>1058-4838</issn><issn>1537-6591</issn><eissn>1537-6591</eissn><abstract>Abstract In countries with high human immunodeficiency virus (HIV) prevalence, up to 30% of pregnant women are living with HIV, with fetal exposure to both HIV and antiretroviral therapy during pregnancy. In addition, pregnant women without HIV but at high risk of HIV acquisition are increasingly receiving HIV preexposure antiretroviral prophylaxis (PrEP). Investments are being made to establish and follow cohorts of children to evaluate the long-term effects of in utero HIV and antiretroviral exposure. Agreement on a key set of definitions for relevant exposures and outcomes is important both for interpreting individual study results and for comparisons across cohorts. Harmonized definitions of in utero HIV and antiretroviral drug (maternal treatment or PrEP) exposure will also facilitate improved classification of these exposures in future observational studies and clinical trials. The proposed definitions offer a uniform approach to facilitate the consistent description and estimation of effects of HIV and antiretroviral exposures on key child health outcomes. In countries with high human immunodeficiency virus (HIV) prevalence, 20%–30% of pregnant women have HIV and receive antiretrovirals. Proposed definitions offer a uniform approach to describing/estimating the effects of in utero HIV and antiretroviral exposure on child health outcomes.</abstract><cop>US</cop><pub>Oxford University Press</pub><pmid>35181789</pmid><doi>10.1093/cid/ciab974</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-8046-9268</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1058-4838
ispartof Clinical infectious diseases, 2022-08, Vol.75 (2), p.347-355
issn 1058-4838
1537-6591
1537-6591
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9410726
source Oxford University Press Journals All Titles (1996-Current); MEDLINE; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection
subjects Anti-HIV Agents - adverse effects
Anti-Retroviral Agents - therapeutic use
Child
Female
HIV
HIV Infections - prevention & control
Humans
Infectious Disease Transmission, Vertical - prevention & control
Pre-Exposure Prophylaxis
Pregnancy
Pregnancy Complications, Infectious - drug therapy
Viewpoints
title Standardized Definitions of In Utero Human Immunodeficiency Virus and Antiretroviral Drug Exposure Among Children
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T00%3A28%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Standardized%20Definitions%20of%20In%20Utero%20Human%20Immunodeficiency%20Virus%20and%20Antiretroviral%20Drug%20Exposure%20Among%20Children&rft.jtitle=Clinical%20infectious%20diseases&rft.au=Slogrove,%20Amy%20L&rft.date=2022-08-25&rft.volume=75&rft.issue=2&rft.spage=347&rft.epage=355&rft.pages=347-355&rft.issn=1058-4838&rft.eissn=1537-6591&rft_id=info:doi/10.1093/cid/ciab974&rft_dat=%3Cproquest_pubme%3E2630926273%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2630926273&rft_id=info:pmid/35181789&rft_oup_id=10.1093/cid/ciab974&rfr_iscdi=true